A detailed history of Corient Capital Partners, LLC transactions in Sorrento Therapeutics, Inc. stock. As of the latest transaction made, Corient Capital Partners, LLC holds 14,913 shares of SRNE stock, worth $4,921. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,913
Previous 14,913 -0.0%
Holding current value
$4,921
Previous $30,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$1.24 - $2.33 $18,492 - $34,747
14,913 New
14,913 $30,000

Others Institutions Holding SRNE

About Sorrento Therapeutics, Inc.


  • Ticker SRNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 449,952,000
  • Market Cap $148M
  • Description
  • Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...
More about SRNE
Track This Portfolio

Track Corient Capital Partners, LLC Portfolio

Follow Corient Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corient Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corient Capital Partners, LLC with notifications on news.